Methylation of tumor suppressor genes in ovarian cancer

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1092-1096

  Ozdemir, Filiz ^a   Altinisik, Julide ^a   Karateke, Ates ^b   Coksuer, Hakan ^b   Buyru, Nur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Zeynep Kamil Maternity and Child Research and Training Hospital   (Turkey)

Author keywords

Methylation; Methylation specific multiplex ligation dependent probe amplification; Ovarian cancer; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLICE INHIBITORY PROTEIN; RETINOIC ACID RECEPTOR BETA; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 84867261513     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.715     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Clark TG, Stewart ME, Altman DG, Gabra H and Smyth JF: A prognostic model for ovarian cancer. Br J Cancer 85: 944-952, 2001.
3. Baylin SB and Herman JG: DNA methylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
4. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996.
5. Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999.
6. Wilson AS, Power BE and Molloy PL: DNA hypomethylation and human diseases. Biochem Biophys Acta 1775: 138-162, 2007.
7. Jones PA: The DNA methylation paradox. Trends Genet 15: 34-37, 1999.
8. Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev 18: 2315-2335, 2004.
9. Laird PW: Cancer epigenetics. Hum Mol Genet 14: R65-R76, 2005.
10. Ducasse M and Brown MA: Epigenetic aberrations and cancer. Mol Cancer 5: 60, 2006.
11. Paluszczak J and Baer-Dubowska W: Epigenetic diagnostics of cancer - the application of DNA methylation markers. J Appl Genet 47: 365-375, 2006.
12. Barton CA, Hacker NF, Clark SJ and O'Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109: 129-139, 2008.
13. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA and Welcsh P: Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8: 48, 2009.
14. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res 64: 6476-6481, 2004.
15. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11: 5365-5369, 2005.
16. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA and Gazdar AF: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331, 2002.
17. Yuecheng Y, Hongmei L and Xiaoyan X: Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 23: 65-74, 2006.
18. Tam KF, Liu VW, Liu SS, Tsang PC, Cheung AN, Yip AM and Ngan HY: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol 133: 331-341, 2007.
19. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158: 1121-1127, 2001.
20. Kiwerska K, Rydzanicz M, Kram A, Pastok M, Antkowiak A, Domagala W and Szyfter K: Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients. Mol Biol Rep 37: 325-332, 2010.
21. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138, 2000.
22. Mehrotra J, Ganpat MM, Kanan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C and Sukumar S: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 10: 2052-2057, 2004.
23. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP and Errami A: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33: e128, 2005.
24. Warnecke PM and Bestor TH: Cytosine methylation and human cancer. Curr Opin Oncol 12: 68-73, 2000.
25. El-Osta A, Baker EK and Wolffe AP: Profiling methyl-CpG specific determinants on transcriptionally silent chromatin. Mol Biol Rep 28: 209-215, 2001.
26. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
27. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
28. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, Brown I, Williams AR, Bates PA, Smyth JF and Garba H: OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34: 337-343, 2003.
29. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967, 2005.
30. Wakana K, Akiyama Y, Aso T and Yuasa Y: Involvement of GATA-4/5 transcription factors in ovarian carcinogenesis. Cancer Lett 241: 281-288, 2006.
31. Milde-Langosch K, Ocon E, Becker G and Löning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79: 61-65, 1998.
32. Kudoh K, Ichikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M and Uchida K: Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 99: 579-582, 2002.
33. Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR and Berchuck A: Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 17: 585-593, 2008.
34. Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH and An HJ: Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 30: 205-217, 2011.
35. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12: 845-859, 1998.
36. Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6: 212, 2006.
37. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K and Murata Y: Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 74: 148-155, 1997.
38. Dodge JE, Munson C and List AF: KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leukemia Res 25: 917-925, 2001.
39. Aggerholm A, Guldberg P, Hokland M and Hokland P: Extensive intra-and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 59: 436-441, 1999.
40. Herman JG, Jen J, Merlo A and Baylin SB: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727, 1996.
41. Wang Y, Zhang D, Zheng W, Luo J, Bai Y and Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112: 1325-1336, 2008.
42. Buyru N, Altinisik J, Ozdemir F, Demokan S and Dalay N: Methylation profiles in breast cancer. Cancer Invest 27: 307-312, 2009.
43. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML and Wei Q: Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 11: 4968-4976, 2005.
44. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI and Shridhar V: Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 15: 715-720, 1999.
45. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001.
46. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 6: 45, 2007.
47. Dammann R, Schagdarsurengin U, Seidal C, Strunnikova M, Rastetter M, Baier K and Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645-663, 2005.
48. Yoon JH, Dammann R and Pfeifer GP: Hypermethylation of the CpG island of RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94: 212-217, 2001.
49. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 20: 1509-1518, 2001.